Feature | September 15, 2014

Improved Survival Shown in Early-stage Hodgkin’s Disease Patients Who Receive Radiation Therapy

Study included more than 41,000 patients across the United States from 1998 to 2011

September 15, 2014 — Patients with stage I and II Hodgkin’s Disease who receive consolidated radiation therapy (RT) have a higher 10-year survival rate of 84 percent, compared to 76 percent for patients who did not receive RT; and, the data also shows a decrease in utilization of RT, according to research presented at the American Society for Radiation Oncology’s (ASTRO’s) 56th Annual Meeting.

Researchers evaluated clinical features and survival outcomes among 41,502 patients diagnosed with stage I and II Hodgkin’s Disease from 1998 to 2011 from a prospectively collected database—the National Cancer Data Base (NCDB), which is comprised of cases from 1,500 sites and represents >75 percent of all cancers diagnosed in the United States. The average patient age was 37 (range: 18 – 90), with a median follow-up of 7.5 years. The association between RT use, co-variables and outcome were assessed in a multivariate Cox proportional hazards model. Survival was estimated using the Kaplan-Meier method.

Multi-agent chemotherapy was administered to 96 percent (39,842) of the patients, and 49 percent (20,441) of patients received a median RT dose of 30.6 Gy. The 10-year overall survival of the entire group was 80.8 percent, with patients receiving RT having a statistically significant improved overall survival rate at 10 years, when compared to those not receiving RT (84.4 percent vs. 76.4 percent; p<0.00001). Additionally, the omission of RT was related to higher rates of salvage transplant procedures performed.

Despite this benefit, the utilization of RT for patients with early-stage Hodgkin’s Disease decreased at the study sites from 56 percent to 41 percent between 1998 and 2011; and in 88.4 percent of the patients, the physician-reported reason given for not administering RT was that it was not part of the planned initial treatment strategy. The research also indicated that RT use was associated with younger patients (=40 years), who are in a higher socioeconomic status, who had access to health insurance, and who received treatment at comprehensive cancer centers (all p<0.0001).

“Multiple prospective, randomized trials have shown a significant improvement in disease control with the addition of RT, however previous trials were limited by low patient numbers and limited follow-up and thus, were unable to demonstrate an overall survival benefit,” said lead study author Rahul R. Parikh, M.D., a radiation oncologist at Mount Sinai Beth Israel and an Assistant Professor of Radiation Oncology at Icahn School of Medicine at Mount Sinai. “This is the largest dataset in this patient population to demonstrate a survival benefit with the addition of RT. Given that the utilization of RT was associated with younger age, insurance status, higher socioeconomic status, and treatment at comprehensive cancer centers, we have highlighted ongoing disparities in Hodgkin’s Disease treatment and it is important that we recognize these findings as potential barriers to care. Given the survival benefit demonstrated in this study, radiotherapy should be included in the combined modality approach of multi-agent chemotherapy followed by consolidation RT in order to maintain high overall survival rates for this curable disease.”

For more information: www.astro.org

Related Content

Top Score in Multiple Brain Metastases TROG 2018 Treatment Plan Study Achieved With Accuray Precision

Image courtesy of Accuray Inc.

News | Treatment Planning | May 24, 2018
Daniela Schmitt, Ph.D., took top honors in the overall category of the 2018 TROG Plan Study: Stereotactic Radiosurgery...
News | Computed Tomography (CT) | May 21, 2018
The Istituto Oncologico Veneto (IOV) in Padua, Italy, has acquired MILabs’ latest-generation Versatile Emission...
Mercy Signs Multi-System, Multi-Hospital Agreement for Accuray Radiotherapy Systems
News | Radiation Therapy | May 16, 2018
Accuray Inc. signed a multi-system, multi-hospital agreement with Mercy for the acquisition of Accuray Radixact and...
ViewRay Unveils New Soft Tissue Visualization Technologies for MRIdian Linac
News | Image Guided Radiation Therapy (IGRT) | April 30, 2018
ViewRay Inc. announced new magnetic resonance imaging (MRI) technologies under development for its MRIdian Linac...
MedStar Georgetown Conducts World's First Hyperscan Proton Therapy Treatment
News | Proton Therapy | April 27, 2018
For the first time, cancer patients in the Washington, D.C. metropolitan region have access to proton therapy, now...
Designed to support a broad range of planning and delivery technologies, SunCheck 2.0 streamlines and standardizes workflows, allowing greater overall focus on patient safety.
Technology | Quality Assurance (QA) | April 27, 2018
Sun Nuclear Corp. released significant new functionality for its SunCheck Platform for patient and machine quality...
RayStation Users Win Inaugural Treatment Planning World Championships
News | Treatment Planning | April 27, 2018
In the first World Championships of Treatment Planning, arranged by radiation oncology analytics company ProKnow and...
Brainlab Introduces New Hi-Res Planning Algorithm for VersaHD
News | Treatment Planning | April 24, 2018
Brainlab announced the implementation of a software solution that can achieve better radiation dose conformity around...
Shorter Radiotherapy Courses Safe and Effective for Prostate Cancer
News | Prostate Cancer | April 23, 2018
Radiotherapy given in high doses over a shorter period of time is safe and effective for prostate cancer patients,...
Elekta Expands Mosaiq Oncology Information System With PalabraApps
News | Oncology Information Management Systems (OIMS) | April 20, 2018
April 20, 2018 — Elekta announced that it is making a strategic investment in PalabraApps LLC to advance the developm
Overlay Init